PureTech to Present LYT-200 Phase 1b Results at ESMO 2026
PureTech Health said on October 19, 2026 that completed Phase 1b results for LYT-200 will be presented at the ESMO Congress 2026 in Madrid on October 24. The announcement described encouraging clinical activity and favorable safety in heavily pretreated patients with R/R HR-MDS and AML, while wholly owned subsidiary Gallop Oncology plans a Phase 2 STRIDE-MDS trial after an FDA End-of-Phase 1 meeting and Fast Track designation.
Why it matters
The announcement could move LYT-200 toward Phase 2 development in R/R HR-MDS. PureTech and Gallop Oncology plan to advance the drug, subject to the stated development path and regulatory designation.
Key facts
- 1The oral presentation is scheduled for October 24, 2026, from 8:30 AM to 10:00 AM CEST. finanznachrichten.de
- 2LYT-200 has received Fast Track designation from the U.S. FDA for R/R HR-MDS in combination with a hypomethylating agent and for AML. finanznachrichten.de
- 3Gallop Oncology is wholly owned by PureTech Health. finanznachrichten.de
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.